Candriam S.C.A. Celcuity Inc. Transaction History
Candriam S.C.A.
- $18.4 Billion
- Q3 2025
A detailed history of Candriam S.C.A. transactions in Celcuity Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 390,924 shares of CELC stock, worth $36.1 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
390,924
Previous 263,576
48.32%
Holding current value
$36.1 Million
Previous $3.52 Million
446.13%
% of portfolio
0.1%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding CELC
# of Institutions
186Shares Held
38.2MCall Options Held
574KPut Options Held
205K-
Baker Bros. Advisors LP New York, NY7.92MShares$732 Million3.17% of portfolio
-
Perceptive Advisors LLC New York, NY2.96MShares$273 Million0.32% of portfolio
-
Nea Management Company, LLC Timonium, MD2.14MShares$198 Million6.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.06MShares$190 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.51MShares$140 Million0.0% of portfolio
About Celcuity Inc.
- Ticker CELC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,941,300
- Market Cap $1.38B
- Description
- Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...